Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290578 | 0.87 | S1PR3 (1.00) | S1PR3 | |
| SCHEMBL12131497 | 0.86 | S1PR3 (0.77) | S1PR3 | |
| SCHEMBL1350665 | 0.86 | S1PR3 (0.77) | S1PR3 | |
| SCHEMBL12131384 | 0.85 | S1PR3 (0.81) | S1PR3 | |
| SCHEMBL805671 | 0.85 | S1PR3 (1.00) | S1PR3 | |
| SCHEMBL805698 | 0.85 | S1PR3 (1.00) | S1PR3 | |
| SCHEMBL14110580 | 0.85 | S1PR3 (0.84) | S1PR3 | |
| SCHEMBL4883379 | 0.85 | S1PR3 (1.00) | S1PR3 | |
| SCHEMBL12131439 | 0.84 | S1PR3 (0.78) | S1PR3 | |
| SCHEMBL13764667 | 0.84 | S1PR3 (0.85) | S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303878-B1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2013-06-12 | — | — | EP | claimed |
| US-8012992-B2 | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | claimed |
| EP-2303878-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2010002820-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20090325970-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-12-31 | — | — | US | claimed |
| US-8536339-B2 | AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536339-B2 | AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536339-B2 | AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2303878-B1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2303878-B1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8263767-B2 | AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263767-B2 | AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8012992-B2 | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012992-B2 | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2303878-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010002820-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002820-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090325970-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325970-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325970-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325970-A1 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | S1PR1, S1PR2, S1PR3 | S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.